| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Are Overcome to Control Infection with Leishmania donovani in CC Chemokine Receptor (CCR) 5-, Macrophage Inflammatory Protein-1
-, or CCR2-Deficient Mice1
*
South Texas Veterans Health Care System, Audie L. Murphy Division, Departments of
Medicine and
Pathology, University of Texas Health Science Center, San Antonio, TX 78229;
§
Section of Molecular Genetics and Microbiology and
¶
Institute of Cellular and Molecular Biology, University of Texas, Austin, TX 78712; and
||
Department of Pathology and Laboratory Medicine, University of North Carolina Medical School, Chapel Hill, NC 27599
We investigated the immune responses in mice lacking CCR2, CCR5, or
macrophage inflammatory protein-1
(MIP-1), a ligand for CCR5, in
two situations: following T cell stimulation or after challenge with
Leishmania donovani, an intracellular microbe whose
control is dependent on a Th1 immune response. Mice deficient in CCR5,
MIP-1, or CCR2 had reduced IFN-
responses following ligation of
the TCR. Reduced IFN- responses following PMA and ionomycin were
also observed in CD8+ T cells of CCR5-/- and
CCR2-/- mice. During the early phases of infection, all
three knockout mice had low Ag-specific IFN- responses. However,
this reduced IFN- response was overcome during a state of persistent
Ag stimulation (chronic infection), and was not associated with an
adverse parasitologic outcome in any of the gene-targeted mouse
strains. To the contrary, during the late phase of infection, an
exaggerated Ag-specific IFN- response was evident in
CCR5-/- and MIP-1-/- mice, and this
correlated with an enhanced control of parasite replication. Although
granuloma formation was abnormal in each of the knockout mice, there
was no correlation between the number or architecture of the granulomas
and parasite burden. Collectively, these findings indicate
an important role for CCR5, MIP-1, and CCR2 in granulomatous
inflammation, and that CCR5 and MIP-1, possibly acting through CCR5,
might play a deleterious role in the outcome of chronic L.
donovani infection. Our data also suggest that there might be
cross-talk between TCR and chemokine receptor signaling
pathways.
This article has been cited by other articles:
|
|
 |
|
  S. M. Bokhari, K.-J. Kim, D. M. Pinson, J. Slusser, H.-W. Yeh, and M. J. Parmely NK Cells and Gamma Interferon Coordinate the Formation and Function of Hepatic Granulomas in Mice Infected with the Francisella tularensis Live Vaccine Strain Infect. Immun., April 1, 2008; 76(4): 1379 - 1389. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Meagher, G. Arreaza, A. Peters, C. A. Strathdee, P. A. Gilbert, Q.-S. Mi, P. Santamaria, G. A. Dekaban, and T. L. Delovitch CCL4 Protects From Type 1 Diabetes by Altering Islet {beta}-Cell-Targeted Inflammatory Responses Diabetes, March 1, 2007; 56(3): 809 - 817. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Iannuzzi and B. A. Rybicki Genetics of Sarcoidosis: Candidate Genes and Genome Scans Proceedings of the ATS, January 1, 2007; 4(1): 108 - 116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Cid, M. P. Hoffman, J. Hernandez-Rodriguez, M. Segarra, M. Elkin, M. Sanchez, C. Vilardell, A. Garcia-Martinez, M. Pla-Campo, J. M. Grau, et al. Association between increased CCL2 (MCP-1) expression in lesions and persistence of disease activity in giant-cell arteritis Rheumatology, November 1, 2006; 45(11): 1356 - 1363. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Yurchenko, M. Tritt, V. Hay, E. M. Shevach, Y. Belkaid, and C. A. Piccirillo CCR5-dependent homing of naturally occurring CD4+ regulatory T cells to sites of Leishmania major infection favors pathogen persistence J. Exp. Med., October 30, 2006; 203(11): 2451 - 2460. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. K. Henke, C. G. Pearce, D. M. Moaveni, A. J. Moore, E. M. Lynch, C. Longo, M. Varma, N. A. Dewyer, K. B. Deatrick, G. R. Upchurch Jr, et al. Targeted Deletion of CCR2 Impairs Deep Vein Thombosis Resolution in a Mouse Model. J. Immunol., September 1, 2006; 177(5): 3388 - 3397. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Palaniappan, S. Singh, U. P. Singh, R. Singh, E. W. Ades, D. E. Briles, S. K. Hollingshead, W. Royal III, J. S. Sampson, J. K. Stiles, et al. CCL5 Modulates Pneumococcal Immunity and Carriage J. Immunol., February 15, 2006; 176(4): 2346 - 2356. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Hardison, R. A. Wrightsman, P. M. Carpenter, W. A. Kuziel, T. E. Lane, and J. E. Manning The CC Chemokine Receptor 5 Is Important in Control of Parasite Replication and Acute Cardiac Inflammation following Infection with Trypanosoma cruzi Infect. Immun., January 1, 2006; 74(1): 135 - 143. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Wysocki, Q. Jiang, A. Panoskaltsis-Mortari, P. A. Taylor, K. P. McKinnon, L. Su, B. R. Blazar, and J. S. Serody Critical role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease Blood, November 1, 2005; 106(9): 3300 - 3307. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Goulding, A Murphy, G MacDonald, S Barrett, J Crowe, J Hegarty, S McKiernan, and D Kelleher The CCR5-{Delta}32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source Gut, August 1, 2005; 54(8): 1157 - 1161. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Robben, M. LaRegina, W. A. Kuziel, and L. D. Sibley Recruitment of Gr-1+ monocytes is essential for control of acute toxoplasmosis J. Exp. Med., June 6, 2005; 201(11): 1761 - 1769. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. Hokeness, W. A. Kuziel, C. A. Biron, and T. P. Salazar-Mather Monocyte Chemoattractant Protein-1 and CCR2 Interactions Are Required for IFN-{alpha}/{beta}-Induced Inflammatory Responses and Antiviral Defense in Liver J. Immunol., February 1, 2005; 174(3): 1549 - 1556. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. HAILU, T. VAN DER POLL, N. BERHE, and P. A. KAGER ELEVATED PLASMA LEVELS OF INTERFERON (IFN)-{gamma}, IFN-{gamma} INDUCING CYTOKINES, AND IFN-{gamma} INDUCIBLE CXC CHEMOKINES IN VISCERAL LEISHMANIASIS Am J Trop Med Hyg, November 1, 2004; 71(5): 561 - 567. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B.-C. Chiu, C. M. Freeman, V. R. Stolberg, J. S. Hu, K. Zeibecoglou, B. Lu, C. Gerard, I. F. Charo, S. A. Lira, and S. W. Chensue Impaired Lung Dendritic Cell Activation in CCR2 Knockout Mice Am. J. Pathol., October 1, 2004; 165(4): 1199 - 1209. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Scott Algood and J. L. Flynn CCR5-Deficient Mice Control Mycobacterium tuberculosis Infection despite Increased Pulmonary Lymphocytic Infiltration J. Immunol., September 1, 2004; 173(5): 3287 - 3296. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Wysocki, S. B. Burkett, A. Panoskaltsis-Mortari, S. L. Kirby, A. D. Luster, K. McKinnon, B. R. Blazar, and J. S. Serody Differential Roles for CCR5 Expression on Donor T Cells during Graft-versus-Host Disease Based on Pretransplant Conditioning J. Immunol., July 15, 2004; 173(2): 845 - 854. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. W. DePaolo, R. Lathan, and W. J. Karpus CCR5 Regulates High Dose Oral Tolerance by Modulating CC Chemokine Ligand 2 Levels in the GALT J. Immunol., July 1, 2004; 173(1): 314 - 320. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Schecter, A. B. Berman, L. Yi, H. Ma, C. M. Daly, K. Soejima, B. J. Rollins, I. F. Charo, and M. B. Taubman MCP-1-dependent signaling in CCR2-/- aortic smooth muscle cells J. Leukoc. Biol., June 1, 2004; 75(6): 1079 - 1085. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. X. Zhong, W. A. Kuziel, E. G. Pamer, and N. V. Serbina Chemokine Receptor 5 Is Dispensable for Innate and Adaptive Immune Responses to Listeria monocytogenes Infection Infect. Immun., February 1, 2004; 72(2): 1057 - 1064. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Szabo, M. A. Wetzel, N. Zhang, A. D. Steele, D. E. Kaminsky, C. Chen, L.-Y. Liu-Chen, F. Bednar, E. E. Henderson, O. M. Z. Howard, et al. Selective inactivation of CCR5 and decreased infectivity of R5 HIV-1 strains mediated by opioid-induced heterologous desensitization J. Leukoc. Biol., December 1, 2003; 74(6): 1074 - 1082. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. Spagnolo, E. A. Renzoni, A. U. Wells, H. Sato, J. C. Grutters, P. Sestini, A. Abdallah, E. Gramiccioni, H. J. T. Ruven, R. M. du Bois, et al. C-C Chemokine Receptor 2 and Sarcoidosis: Association with Lofgren's Syndrome Am. J. Respir. Crit. Care Med., November 15, 2003; 168(10): 1162 - 1166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Rao, M. P. Quinones, E. Garavito, Y. Kalkonde, F. Jimenez, C. Gibbons, J. Perez, P. Melby, W. Kuziel, R. L. Reddick, et al. CC Chemokine Receptor 2 Expression in Donor Cells Serves an Essential Role in Graft-versus-Host-Disease J. Immunol., November 1, 2003; 171(9): 4875 - 4885. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. W. DePaolo, B. J. Rollins, W. Kuziel, and W. J. Karpus CC Chemokine Ligand 2 and Its Receptor Regulate Mucosal Production of IL-12 and TGF-{beta} in High Dose Oral Tolerance J. Immunol., October 1, 2003; 171(7): 3560 - 3567. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Huang and L. D. Hazlett Analysis of Pseudomonas aeruginosa Corneal Infection Using an Oligonucleotide Microarray Invest. Ophthalmol. Vis. Sci., August 1, 2003; 44(8): 3409 - 3416. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. R. Brown, V. A. Blaho, and C. M. Loiacono Susceptibility to Experimental Lyme Arthritis Correlates with KC and Monocyte Chemoattractant Protein-1 Production in Joints and Requires Neutrophil Recruitment Via CXCR2 J. Immunol., July 15, 2003; 171(2): 893 - 901. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Belnoue, F. T. M. Costa, A. M. Vigario, T. Voza, F. Gonnet, I. Landau, N. van Rooijen, M. Mack, W. A. Kuziel, and L. Renia Chemokine Receptor CCR2 Is Not Essential for the Development of Experimental Cerebral Malaria Infect. Immun., June 1, 2003; 71(6): 3648 - 3651. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Belnoue, M. Kayibanda, J.-C. Deschemin, M. Viguier, M. Mack, W. A. Kuziel, and L. Renia CCR5 deficiency decreases susceptibility to experimental cerebral malaria Blood, June 1, 2003; 101(11): 4253 - 4259. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Lillard Jr, U. P. Singh, P. N. Boyaka, S. Singh, D. D. Taub, and J. R. McGhee MIP-1alpha and MIP-1beta differentially mediate mucosal and systemic adaptive immunity Blood, February 1, 2003; 101(3): 807 - 814. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. G. Glass and T. E. Lane Functional Expression of Chemokine Receptor CCR5 on CD4+ T Cells during Virus-Induced Central Nervous System Disease J. Virol., December 6, 2002; 77(1): 191 - 198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Scott and J. L. Flynn Mycobacterium tuberculosis in Chemokine Receptor 2-Deficient Mice: Influence of Dose on Disease Progression Infect. Immun., November 1, 2002; 70(11): 5946 - 5954. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J. D. Mennechet, L. H. Kasper, N. Rachinel, W. Li, A. Vandewalle, and D. Buzoni-Gatel Lamina Propria CD4+ T Lymphocytes Synergize with Murine Intestinal Epithelial Cells to Enhance Proinflammatory Response Against an Intracellular Pathogen J. Immunol., March 15, 2002; 168(6): 2988 - 2996. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Nansen, J. P. Christensen, S. O. Andreasen, C. Bartholdy, J. E. Christensen, and A. R. Thomsen The role of CC chemokine receptor 5 in antiviral immunity Blood, February 15, 2002; 99(4): 1237 - 1245. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. P. Chen, W. A. Kuziel, and T. E. Lane Lack of CCR2 Results in Increased Mortality and Impaired Leukocyte Activation and Trafficking Following Infection of the Central Nervous System with a Neurotropic Coronavirus J. Immunol., October 15, 2001; 167(8): 4585 - 4592. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Strizki, S. Xu, N. E. Wagner, L. Wojcik, J. Liu, Y. Hou, M. Endres, A. Palani, S. Shapiro, J. W. Clader, et al. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo PNAS, October 12, 2001; (2001) 221375398. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Peters, H. M. Scott, H. F. Chambers, J. L. Flynn, I. F. Charo, and J. D. Ernst Chemokine receptor 2 serves an early and essential role in resistance to Mycobacterium tuberculosis PNAS, July 3, 2001; 98(14): 7958 - 7963. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-J. ANDERS, V. VIELHAUER, M. KRETZLER, C. D. COHEN, S. SEGERER, B. LUCKOW, L. WELLER, H.-J. GRÖNE, and D. SCHLÖNDORFF Chemokine and Chemokine Receptor Expression during Initiation and Resolution of Immune Complex Glomerulonephritis J. Am. Soc. Nephrol., May 1, 2001; 12(5): 919 - 931. [Abstract] [Full Text]
|
|
|
|
|
|
Y. Kim, S.-s. J. Sung, W. A. Kuziel, S. Feldman, S. M. Fu, and C. E. Rose Jr Enhanced Airway Th2 Response After Allergen Challenge in Mice Deficient in CC Chemokine Receptor-2 (CCR2) J. Immunol., April 15, 2001; 166(8): 5183 - 5192. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Lillard Jr., P. N. Boyaka, D. D. Taub, and J. R. McGhee RANTES Potentiates Antigen-Specific Mucosal Immune Responses J. Immunol., January 1, 2001; 166(1): 162 - 169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Peters, M. Dupuis, and I. F. Charo A Mechanism for the Impaired IFN-{gamma} Production in C-C Chemokine Receptor 2 (CCR2) Knockout Mice: Role of CCR2 in Linking the Innate and Adaptive Immune Responses J. Immunol., December 15, 2000; 165(12): 7072 - 7077. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. MacLean, G. T. De Sanctis, K. G. Ackerman, J. M. Drazen, A. Sauty, E. DeHaan, F. H. Y. Green, I. F. Charo, and A. D. Luster CC Chemokine Receptor-2 Is Not Essential for the Development of Antigen-Induced Pulmonary Eosinophilia and Airway Hyperresponsiveness J. Immunol., December 1, 2000; 165(11): 6568 - 6575. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. , G. , W. , and W. CC Chemokine Receptor 2 Is Critical for Induction of Experimental Autoimmune J. Exp. Med., September 18, 2000; 192(6): 899 - 906. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Petrek, J. ZLÁMAL, K. I. WELSH, M. BUNCE, and R. BOIS CC Chemokine Receptor Gene Polymorphisms in Czech Patients with Pulmonary Sarcoidosis Am. J. Respir. Crit. Care Med., September 1, 2000; 162(3): 1000 - 1003. [Abstract] [Full Text]
|
|
|
|
|
|
N. Sato, S. K. Ahuja, M. Quinones, V. Kostecki, R. L. Reddick, P. C. Melby, W. A. Kuziel, and S. S. Ahuja CC Chemokine Receptor (CCR)2 Is Required for Langerhans Cell Migration and Localization of T Helper Cell Type 1 (Th1)-inducing Dendritic Cells: Absence of CCR2 Shifts the Leishmania major-resistant Phenotype to a Susceptible State Dominated by Th2 Cytokines, B Cell Outgrowth, and Sustained Neutrophilic Inflammation J. Exp. Med., July 10, 2000; 192(2): 205 - 218. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Strizki, S. Xu, N. E. Wagner, L. Wojcik, J. Liu, Y. Hou, M. Endres, A. Palani, S. Shapiro, J. W. Clader, et al. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo PNAS, October 23, 2001; 98(22): 12718 - 12723. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
